BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wollmer E, Klein S. A review of patient-specific gastrointestinal parameters as a platform for developing in vitro models for predicting the in vivo performance of oral dosage forms in patients with Parkinson’s disease. International Journal of Pharmaceutics 2017;533:298-314. [DOI: 10.1016/j.ijpharm.2017.08.126] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Wollmer E, Klein S. Patient-specific in vitro drug release testing coupled with in silico PBPK modeling to forecast the in vivo performance of oral extended-release levodopa formulations in Parkinson's disease patients. Eur J Pharm Biopharm 2022:S0939-6411(22)00210-7. [PMID: 36150616 DOI: 10.1016/j.ejpb.2022.09.015] [Reference Citation Analysis]
2 Shuklinova O, Dorożyński P, Kulinowski P, Polak S. Quality Control Dissolution Data Is Biopredictive for a Modified Release Ropinirole Formulation: Virtual Experiment with the Use of Re-Developed and Verified PBPK Model. Pharmaceutics 2022;14:1514. [DOI: 10.3390/pharmaceutics14071514] [Reference Citation Analysis]
3 Trapani A, De Giglio E, Cometa S, Bonifacio MA, Dazzi L, Di Gioia S, Hossain MN, Pellitteri R, Antimisiaris SG, Conese M. Dopamine-loaded lipid based nanocarriers for intranasal administration of the neurotransmitter: A comparative study. Eur J Pharm Biopharm 2021;167:189-200. [PMID: 34333085 DOI: 10.1016/j.ejpb.2021.07.015] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Vinarov Z, Abrahamsson B, Artursson P, Batchelor H, Berben P, Bernkop-Schnürch A, Butler J, Ceulemans J, Davies N, Dupont D, Flaten GE, Fotaki N, Griffin BT, Jannin V, Keemink J, Kesisoglou F, Koziolek M, Kuentz M, Mackie A, Meléndez-Martínez AJ, McAllister M, Müllertz A, O'Driscoll CM, Parrott N, Paszkowska J, Pavek P, Porter CJH, Reppas C, Stillhart C, Sugano K, Toader E, Valentová K, Vertzoni M, De Wildt SN, Wilson CG, Augustijns P. Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Adv Drug Deliv Rev 2021;171:289-331. [PMID: 33610694 DOI: 10.1016/j.addr.2021.02.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 30.0] [Reference Citation Analysis]
5 Di Gioia S, Trapani A, Cassano R, Di Gioia ML, Trombino S, Cellamare S, Bolognino I, Hossain MN, Sanna E, Trapani G, Conese M. Nose-to-brain delivery: A comparative study between carboxymethyl chitosan based conjugates of dopamine. Int J Pharm 2021;599:120453. [PMID: 33675929 DOI: 10.1016/j.ijpharm.2021.120453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Stillhart C, Vučićević K, Augustijns P, Basit AW, Batchelor H, Flanagan TR, Gesquiere I, Greupink R, Keszthelyi D, Koskinen M, Madla CM, Matthys C, Miljuš G, Mooij MG, Parrott N, Ungell A, de Wildt SN, Orlu M, Klein S, Müllertz A. Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review. European Journal of Pharmaceutical Sciences 2020;147:105280. [DOI: 10.1016/j.ejps.2020.105280] [Cited by in Crossref: 37] [Cited by in F6Publishing: 58] [Article Influence: 18.5] [Reference Citation Analysis]
7 Govender R, Abrahmsén-alami S, Larsson A, Folestad S. Therapy for the individual: Towards patient integration into the manufacturing and provision of pharmaceuticals. European Journal of Pharmaceutics and Biopharmaceutics 2020;149:58-76. [DOI: 10.1016/j.ejpb.2020.01.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
8 Sharma S, Awasthi A, Singh S. Altered gut microbiota and intestinal permeability in Parkinson’s disease: Pathological highlight to management. Neuroscience Letters 2019;712:134516. [DOI: 10.1016/j.neulet.2019.134516] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
9 Karkossa F, Klein S. Individualized in vitro and in silico methods for predicting in vivo performance of enteric-coated tablets containing a narrow therapeutic index drug. Eur J Pharm Biopharm 2019;135:13-24. [PMID: 30529296 DOI: 10.1016/j.ejpb.2018.12.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
10 Baek JS, Tee JK, Pang YY, Tan EY, Lim KL, Ho HK, Loo SCJ. Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease. Neuromolecular Med 2018;20:262-70. [PMID: 29696585 DOI: 10.1007/s12017-018-8491-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]